• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

FDA requires additional phase 3 trial of Targanta antibiotic

Washington - The Food and Drug Administration (FDA) is requiring Targanta Therapeutics to conduct an additional phase 3 trial of its antibiotic oritavancin, according to fdanews.com.

Washington

- The Food and Drug Administration (FDA) is requiring Targanta Therapeutics to conduct an additional phase 3 trial of its antibiotic oritavancin, according to fdanews.com.

In order for oritavancin NDA to treat complicated skin and skin structure infections, the study must include subjects with methicillin-resistant Staphylococcus aureus, and several safety concerns must be addressed, including a high rate of participants dropping out due to lack of efficacy and serious adverse events, according to the release.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.